Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications

详细信息    查看全文

• 作者：Ignace B. Vergote (1)
  Christian Marth (2)
  Robert L. Coleman (3)
  
  1. Department of Obstetrics and Gynaecolog ; Leuven Cancer Institute ; University Hospital Leuven ; Herestraat 49 ; 3000 ; Leuven ; Belgium
  2. Innsbruck Medical University ; Anichstrasse 35 ; 6020 ; Innsbruck ; Austria
  3. University of Texas MD Anderson Cancer Center ; 1515 Holcombe Blvd. ; Unit 1362 ; Houston ; TX ; 77030-4009 ; USA
  
• 关键词：Folate receptor ; Ovarian cancer ; Biomarker ; Targeted therapy
• 刊名：Cancer and Metastasis Reviews
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：34
• 期：1
• 页码：41-52
• 全文大小：818 KB
• 参考文献：1. Tibbetts, AS, Appling, DR (2010) Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annual Review of Nutrition 3: pp. 57-81 CrossRef
  2. Choi, SW, Mason, JB (2000) Folate and carcinogenesis: an integrated scheme. The Journal of Nutrition 130: pp. 129-132
  3. Stover, PJ (2004) Physiology of folate and vitamin B12 in health and disease. Nutrition Reviews 62: pp. S3-S12 CrossRef
  4. Wani, NA, Hamid, A, Kaur, J (2008) Folate status in various pathophysiological conditions. IUBMB Life 60: pp. 834-842 CrossRef
  5. Zhao, R, Diop-Bove, N, Visentin, M, Goldman, ID (2011) Mechanisms of membrane transport of folates into cells and across epithelia. Annual Review of Nutrition 31: pp. 177-201 CrossRef
  6. Matherly, LH, Hou, Z, Deng, Y (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Reviews 26: pp. 111-128 CrossRef
  7. Kelemen, LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?. International Journal of Cancer 119: pp. 243-250 CrossRef
  8. Matherly, LH, Goldman, DI (2003) Membrane transport of folates. Vitamins and Hormones 66: pp. 403-456 CrossRef
  9. Zhao, R, Goldman, ID (2007) The molecular identity and characterization of a Proton-coupled Folate Transporter鈥揚CFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Reviews 26: pp. 129-139 CrossRef
  10. Salazar, MD, Ratnam, M (2007) The folate receptor: what does it promise in tissue-targeted therapeutics?. Cancer Metastasis Reviews 26: pp. 141-152 CrossRef
  11. Ross, JF, Chaudhuri, PK, Ratnam, M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73: pp. 2432-2443 CrossRef
  12. Xia, W, Hilgenbrink, AR, Matteson, EL, Lockwood, MB, Cheng, JX, Low, PS (2009) A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 113: pp. 438-446 CrossRef
  13. Yamaguchi, T, Hirota, K, Nagahama, K, Ohkawa, K, Takahashi, T, Nomura, T (2007) Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27: pp. 145-159 CrossRef
  14. Kinoshita, M, Kayama, H, Kusu, T, Yamaguchi, T, Kunisawa, J, Kiyono, H (2012) Dietary folic acid promotes survival of Foxp3+ regulatory T cells in the colon. Journal of Immunology 189: pp. 2869-2878 CrossRef
  15. Shen, F, Ross, JF, Wang, X, Ratnam, M (1994) Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 33: pp. 1209-1215 CrossRef
  16. Parker, N, Turk, MJ, Westrick, E, Lewis, JD, Low, PS, Leamon, CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Analytical Biochemistry 338: pp. 284-293 CrossRef
  17. Smith, SB, Kekuda, R, Gu, X, Chancy, C, Conway, SJ, Ganapathy, V (1999) Expression of folate receptor alpha in the mammalian retinol pigmented epithelium and retina. Investigative Ophthalmology & Visual Science 40: pp. 840-848
  18. Solanky, N, Requena, JA, D鈥橲ouza, SW, Sibley, CP, Glazier, JD (2010) Expression of folate transporters in human placenta and implications for homocysteine metabolism. Placenta 31: pp. 134-143 CrossRef
  19. Kamen, BA, Smith, AK (2004) A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Advanced Drug Delivery Reviews 256: pp. 1085-1097 CrossRef
  20. Selhub, J, Emmanouel, D, Stavropoulos, T, Arnold, R (1987) Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. The American Journal of Physiology 252: pp. F750-F756
  21. Smith, AD, Kim, YI, Refsum, H (2008) Is folic acid good for everyone?. The American Journal of Clinical Nutrition 87: pp. 517-533
  22. Siu, MK, Kong, DS, Chan, HY, Wong, ES, Ip, PP, Jiang, L (2012) Paradoxical impact of two folate receptors, FR伪 and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One 7: pp. e47201 CrossRef
  23. Kim, YI (2003) Role of folate in colon cancer development and progression. The Journal of Nutrition 133: pp. 3731S-3739S
  24. Crider, KS, Yang, TP, Berry, RJ, Bailey, LB (2012) Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate鈥檚 role. Advances in Nutrition (Bethesda, Md.) 3: pp. 21-38 CrossRef
  25. Larsson, SC, Giovannucci, E, Wolk, A (2004) Dietary folate intake and incidence of ovarian cancer: the Swedish Mammography Cohort. Journal of the National Cancer Institute 96: pp. 396-402 CrossRef
  26. Giovannucci, E (2002) Epidemiologic studies of folate and colorectal neoplasia: a review. The Journal of Nutrition 132: pp. 2350S-2355S
  27. Zhang, CX, Ho, SC, Chen, YM, Lin, FY, Fu, JH, Cheng, SZ (2011) Dietary folate, vitamin B6, vitamin B12 and methionine intake and the risk of breast cancer by oestrogen and progesterone receptor status. British Journal of Nutrition 106: pp. 936-943 CrossRef
  28. Tavani, A, Malerba, S, Pelucchi, C, Dal, ML, Zucchetto, A, Serraino, D (2012) Dietary folates and cancer risk in a network of case鈥揷ontrol studies. Annals of Oncology 23: pp. 2737-2742 CrossRef
  29. Stolzenberg-Solomon, RZ, Chang, SC, Leitzmann, MF, Johnson, KA, Johnson, C, Buys, SS (2006) Folate intake, alcohol use, and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. The American Journal of Clinical Nutrition 83: pp. 895-904
  30. Kim, YI (2007) Folate and colorectal cancer: an evidence-based critical review. Molecular Nutrition & Food Research 51: pp. 267-292 CrossRef
  31. Hultdin, J, Guelpen, B, Bergh, A, Hallmans, G, Stattin, P (2005) Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. International Journal of Cancer 113: pp. 819-824 CrossRef
  32. Zhang Z., Wang J., Tacha D. E., Li P., Bremer R. E., Chen H., et al. (2014). Folate receptor 伪 associated with triple-negative breast cancer and poor prognosis. / Archives of Pathology & Laboratory Medicine, 138(7):890鈥?95.
  33. Matulonis, UA, Horowitz, NS, Campos, SM, Lee, H, Lee, J, Krasner, CN (2008) Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. Journal of Clinical Oncology 26: pp. 5761-5766 CrossRef
  34. Vergote, I, Calvert, H, Kania, M, Kaiser, C, Zimmermann, AH, Sehouli, J (2009) A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. European Journal of Cancer 45: pp. 1415-1423 CrossRef
  35. Kurkjian C., LoRusso P., Sankhala K. K., Birrer M. J., Kirby M., Ladd S., et al. (2013). A phase 1, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors. / ASCO Meeting Abstracts, 31(15_suppl), 2573.
  36. Ma, DW, Finnell, RH, Davidson, LA, Callaway, ES, Spiegelstein, O, Piedrahita, JA (2005) Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Research 65: pp. 887-897
  37. Desmoulin, SK, Hou, Z, Gangjee, A, Matherly, LH (2012) The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biology & Therapy 13: pp. 1355-1373 CrossRef
  38. Siegel, R, Naishadham, D, Jemal, A (2013) Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63: pp. 11-30
  39. Kalli, KR, Oberg, AL, Keeney, GL, Christianson, TJ, Low, PS, Knutson, KL (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecologic Oncology 108: pp. 619-626 CrossRef
  40. Bagnoli, M, Canevari, S, Figini, M, Mezzanzanica, D, Raspagliesi, F, Tomassetti, A (2003) A step further in understanding the biology of the folate receptor in ovarian carcinoma. Gynecologic Oncology 88: pp. S140-S144 CrossRef
  41. Despierre, E, Lambrechts, S, Leunen, K, Berteloot, P, Neven, P, Amant, F (2013) Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecolic Oncology 130: pp. 192-199 CrossRef
  42. Kelley, KM, Rowan, BG, Ratnam, M (2003) Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Research 63: pp. 2820-2828
  43. Sivakumaran, S, Zhang, J, Kelley, KM, Gonit, M, Hao, H, Ratnam, M (2010) Androgen activation of the folate receptor 伪 gene through partial tethering of the androgen receptor by C/EBP伪. The Journal of Steroid Biochemistry and Molecular Biology 122: pp. 333-340 CrossRef
  44. Shatnawi, A, Tran, T, Ratnam, M (2007) R5020 and RU486 act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism. Molecular Endocrinology (Baltimore, Md.) 21: pp. 635-650 CrossRef
  45. Tran, T, Shatnawi, A, Zheng, X, Kelley, KM, Ratnam, M (2005) Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. Cancer Research 65: pp. 4431-4441 CrossRef
  46. Doucette, MM, Stevens, VL (2001) Folate receptor function is regulated in response to different cellular growth rates in cultured mammalian cells. The Journal of Nutrition 131: pp. 2819-2825
  47. Toffoli, G, Cernigoi, C, Russo, A, Gallo, A, Bagnoli, M, Boiocchi, M (1997) Overexpression of folate binding protein in ovarian cancers. International Journal of Cancer 174: pp. 193-198 CrossRef
  48. Chen, YL, Chang, MC, Huang, CY, Chiang, YC, Lin, HW, Chen, CA (2012) Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Molecular Oncology 6: pp. 360-369 CrossRef
  49. O鈥橲hannessy, DJ, Somers, EB, Smale, R, Fu, YS (2013) Expression of folate receptor-伪 (FRA) in gynecologic malignancies and its relationship to the tumor type. International Journal of Gynecological Pathology 32: pp. 258-268 CrossRef
  50. Despierre, E., Lambrechts, S., Leunen, K., Neven, P., Amant, F., O鈥橲hannessy, D. J., et al. (2012). Folate receptor alpha: potential therapeutic target for pure yolk sac tumors and mixed germ cell tumors with yolk sac component. / International Journal of Gynecological Cancer, 22(8 suppl 3).
  51. Toffoli, G, Russo, A, Gallo, A, Cernigoi, C, Miotti, S, Sorio, R (1998) Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. International Journal of Cancer 179: pp. 121-126 CrossRef
  52. Naumann, RW, Coleman, RL, Burger, RA, Sausville, EA, Kutarska, E, Ghamande, SA (2013) PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. Journal of Clinical Oncology 31: pp. 4400-4406 CrossRef
  53. Cerezo, A, Guadamillas, MC, Goetz, JG, S谩nchez-Perales, S, Klein, E, Assoian, RK (2009) The absence of caveolin-1 increases proliferation and anchorage- independent growth by a Rac-dependent, Erk-independent mechanism. Molecular Cell Biology 29: pp. 5046-5059 CrossRef
  54. Kannan, A, Krishnan, A, Ali, M, Subramaniam, S, Halagowder, D, Sivasithamparam, ND (2014) Caveolin-1 promotes gastric cancer progression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition. European Journal of Cancer 50: pp. 204-215 CrossRef
  55. Yilmaz, M, Christofori, G (2010) Mechanisms of motility in metastasizing cells. Molecular Cancer Research: MCR 8: pp. 629-642 CrossRef
  56. Leamon, CP, Parker, MA, Vlahov, IR, Xu, LC, Reddy, JA, Vetzel, M (2002) Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjugate Chemistry 13: pp. 1200-1210 CrossRef
  57. Teng, L, Xie, J, Teng, L, Lee, RJ (2012) Clinical translation of folate receptor-targeted therapeutics. Expert Opinion on Drug Delivery 9: pp. 901-908 CrossRef
  58. Konner, JA, Bell-McGuinn, KM, Sabbatini, P, Hensley, ML, Tew, WP, Pandit-Taskar, N (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clinical Cancer Research 16: pp. 5288-5295 CrossRef
  59. Armstrong, DK, White, AJ, Weil, SC, Phillips, M, Coleman, RL (2013) Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecologic Oncology 129: pp. 452-458 CrossRef
  60. Vergote I., Armstrong D., Scambia G., Fujiwara K., Gorbunova V., Schweizer C., et al. (2013). Phase 3 double-blind, placebo-controlled study of weekly farletuzumab with carboplatin/taxane in subjects with platinum-sensitive ovarian cancer in first relapse. / International Journal of Gynecological Cancer, 23(8); Supplement 1.
  61. Walters, CL, Arend, RC, Armstrong, DK, Naumann, RW, Alvarez, RD (2013) Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecologic Oncology 131: pp. 493-498 CrossRef
  62. Lorusso, PM, Edelman, MJ, Bever, SL, Forman, KM, Pilat, M, Quinn, MF (2012) Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. Journal of Clinical Oncology 30: pp. 4011-4016 CrossRef
  63. Morris, RT, Joyrich, RN, Naumann, RW, Shah, NP, Maurer, AH, Strauss, HW (2014) Phase 2 study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). Annals of Oncology 25: pp. 852-858 CrossRef
  64. Ebel, W, Routhier, EL, Foley, B, Jacob, S, McDonough, JW, Patel, RK (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immunity 7: pp. 6
  65. Lin, J, Spidel, JL, Maddage, CJ, Rybinski, KA, Kennedy, RP, Krauthauser, CL (2013) The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biology & Therapy 14: pp. 1032-1038 CrossRef
  66. Vlahov, IR, Santhapuram, HK, Kleindl, PJ, Howard, SJ, Stanford, KM, Leamon, CP (2013) Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorganic & Medicinal Chemistry Letters 16: pp. 5093-5096 CrossRef
  67. Reddy, JA, Dorton, R, Westrick, E, Dawson, A, Smith, T, Xu, LC (2007) Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Research 67: pp. 4434-4442 CrossRef
  68. Reddy J. A., Dorton R., Dawson A., Nelson M., Vetzel M., Guan J, et al. (2014). Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.@@ / Clinical Cancer Research, Epub ahead of print.
  69. Chen, H, Zhang, T, Zhou, Z, Guan, M, Wang, J, Liu, L (2013) Enhanced uptake and cytotoxicity of folate-conjugated mitoxantrone-loaded micelles via receptor up-regulation by dexamethasone. International Journal of Pharmaceutics 448: pp. 142-149 CrossRef
  70. Sega, EI, Low, PS (2008) Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Reviews 27: pp. 655-664 CrossRef
  71. Mantovani, LT, Miotti, S, M茅nard, S, Canevari, S, Raspagliesi, F, Bottini, C (1994) Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. European Journal of Cancer 30A: pp. 363-369 CrossRef
  72. Fisher, RE, Siegel, BA, Edell, SL, Oyesiku, NM, Morgenstern, DE, Messmann, RA (2008) Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. Journal of Nuclear Medicine 49: pp. 899-906 CrossRef
  73. Maurer A. H., Elsinga P., Fanti S., Nguyen B., Oyen W. J., Weber W. A. Imaging the folate receptor on cancer cells with ^99mTc-etarfolatide鈥攑roperties, clinical use, and future potential of folate receptor imaging. / Journal of Nuclear Medicine, accepted for publication.
  74. Elnakat, H, Ratnam, M (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Advanced Drug Delivery Reviews 56: pp. 1067-1084 CrossRef
  75. Reddy, JA, Allagadda, VM, Leamon, CP (2005) Targeting therapeutic and imaging agents to folate receptor positive tumors. Current Pharmaceutical Biotechnology 6: pp. 131-150 CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  
• 出版者：Springer Netherlands
• ISSN：1573-7233

文摘

Folate can be transported into the cell by the reduced folate carrier (RFC), the proton-coupled folate transporter (PCFT), or the folate receptor (FR), of which various isoforms exist. While the RFC and PCFT are expressed by many normal cells, the FR is present only in a small proportion of normal tissues. In these tissues, the FR expression level is often low and restricted to the apical surface of polarized epithelial cells. In contrast, FR is expressed on the blood-accessible basal and lateral membranes of many types of epithelial cancer. Considering that FR is expressed in few nonmalignant cell types on luminal membranes generally not accessible for molecules transported in the blood, FR is considered a promising antitumor target. As FR expression seems associated with tumor progression and prognosis, anticancer therapies targeting FR are currently being developed, such as farletuzumab (Morphotek, Exton, PA, USA), IMGN853 (ImmunoGen, Waltham, MA, USA), vintafolide, and EC1456 (both Endocyte Inc., West Lafayette, IN, USA). FR expression could be used as a response-predictive biomarker for these treatments. The ability to identify patients and treat them with an effective therapy based on the known expression of the tumor marker would, indeed, be the next step in predictive medicine for these patients. This review summarizes the role of FR in ovarian cancer and the value of FR as a prognostic biomarker for ovarian cancer and a response-predictive biomarker for folate-targeted therapeutics.